Maja Oroz

Maja Oroz

Auto-generated profile, based on publicly available information

Maja Oroz

Cytogenetic Laboratory, Department of Obstetrics and Gynecology, Clinical Hospital Sveti Duh, 10000 Zagreb, Croatia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2023 in Viruses
Verified
Journal Article
Open access
PDF file
APAna Planinić
Ana Planinić
JBJosip Begovac
Josip Begovac
FRFilip Rokić
Filip Rokić
PSPetra Simicic
Petra Simicic
MOMaja Oroz
Maja Oroz
SLSnjezana Zidovec Lepej
Snjezana Zidovec Lepej
Molecular epidemiology of HIV-1 infection is challenging due to the highly diverse HIV-genome. We investigated the genetic diversity and prevalence of transmitted drug resistance (TDR) followed by phylogenetic analysis in 270 HIV-1 infected, treatment-naïve individuals from Croatia in the period 2019–2022. The results of this research confirmed a high overall prevalence of TDR of 16.7%. Resistance to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside RTIs (NNRTIs), and protease inhibitors (PIs) was found in 9.6%, 7.4%, and 1.5% of persons, respectively. No resistance to integrase strand-transfer inhibitors (INSTIs) was found. Phylogenetic analysis revealed that 173/229 sequences (75.5%) were part of transmission clusters, and the largest identified was T215S, consisting of 45 sequences. Forward transmission was confirmed in several clusters. We compared deep sequencing (DS) with Sanger sequencing (SS) on 60 randomly selected samples and identified additional surveillance drug resistance mutations (SDRMs) in 49 of them. Our data highlight the need for baseline resistance testing in treatment-naïve persons. Although no major INSTIs were found, monitoring of SDRMs to INSTIs should be continued due to the extensive use of first- and second-generation INSTIs.

6 January 2023 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
MHMatija Horaček
Matija Horaček
TNTamara Nikuševa-Martić
Tamara Nikuševa-Martić
PŠPetar Šenjug
Petar Šenjug
MPMarija Šenjug Perica
Marija Šenjug Perica
MOMaja Oroz
Maja Oroz
DLDanica Galešić Ljubanović
Danica Galešić Ljubanović
Alport syndrome (AS) and thin basement membrane nephropathy (TBMN) are part of the spectrum of kidney disorders caused by pathogenic variants in α3, α4, or α5 chains of the collagen type IV, the major structural component of the glomerular basement membrane (GBM). Using targeted next-generation sequencing (NGS), 34 AS/TBMN patients (58.8% male) from 12 unrelated families were found positive for heterozygous c.2881+1G>A variant of the COL4A3gene, that is considered disease-causing. All patients were from the continental or island part of Croatia. Clinical, laboratory, and histopathological data collected from the medical records were analyzed and compared to understand the clinical course and prognosis of the affected patients. At the time of biopsy or first clinical evaluation, the mean age was 31 years (median: 35 years; range: 1 – 72 years). Hematuria was present in 33 patients (97.1%) and 19 (55.9%) patients had proteinuria. There were 6 (17.6%) patients with hearing loss, 4 (11.8%) with ocular lesions, and 11 (32.4%) with hypertension. Twenty-three (67.6%) patients had proteinuria at follow-up, and 5 (14.7%) patients with the median age of 48 years (range: 27-55) progressed to kidney failure, started dialysis, or underwent kidney transplantation. Of the 13 patients who underwent kidney biopsy, 4 (30.8%) developed focal segmental glomerulosclerosis (FSGS), and 8 (66.7%) showed lamellation of the GBM, including all patients with FSGS. It is essential to conduct a detailed analysis of each collagen type IV genetic variant to optimize the prognosis and therapeutic approach for affected patients.

17 April 2023 in Lijecnicki Vjesnik
Verified
Journal Article
Open access
PDF file
FSFeodora Stipoljev
Feodora Stipoljev
MOMaja Oroz
Maja Oroz
AVAna Vičić
Ana Vičić
Genetska testiranja kod pacijenata s neurorazvojnim poremećajima vrlo su važna za postavljanje konačne dijagnoze. Prema trenutnim smjernicama prve metode izbora uključuju komparativnu genomsku hibridizaciju na mikropostroju te genetsko testiranje fra...